Fodor says. For higher cell numbers and for whole-genome coverage, sequencing capacity would become a limiting factor. ■
T-cell Therapy Targets Glioblastoma
A team of researchers successfully engineered T cells to express a chimeric antigen receptor (CAR) that targets a mutation associated with a particularly aggressive form of glioblastoma, laying the foundation for a phase I clinical trial.
In a preclinical study, researchers redirected humanized CAR T cells to bind to the EGFR variant III mutation (EGFRvIII), a common variant of EGFR in human tumors that occurs in about 30% of patients with glioblastoma and is associated with poorer prognosis. Investigators designed CAR T cells using humanized singlechain variable fragments (scFv) that showed specifi city for EGFRvIII over wild-type EGFR. In mice, the EGFRvIII CAR T cells successfully controlled tumor growth, and deeper regression was observed when they were combined with temozolomide chemotherapy, a standard treatment for glioblastoma (Sci Transl Med 2015; 7:275ra22) .
"Studying genetically engineered T cells is a hot area because of the tremendous success there has been with leukemia," says the study's senior author Marcela Maus, MD, PhD, assistant professor of hematology/ oncology at the University of Pennsylvania Abramson Cancer Center in Philadelphia. "This phase I trial will be the fi rst time that we are trying this particular method of engineering T cells to target glioblastoma in humans."
Although CAR T-cell therapy has shown promise for treating blood cancers, solid tumors have been more challenging because many targetable surface antigens on solid tumors are also expressed in normal cells. However, the authors noted that EGFRvIII might be an ideal CAR target because it is specifi c to malignant cells and plays a critical role in maintaining oncogenesis.
The researchers, including scientists from Novartis Institutes for BioMedical Research, tested a panel of scFvs in silico and in vitro in order to determine the degree of specifi city to EGFRvIII and cross specifi city with wild-type EGFR. They then further tested the lead humanized CAR for safety in mouse models grafted with normal EGFRexpressing human skin.
The investigators also tested the lead humanized CAR for effi cacy in three mouse models implanted with human glioblastoma cell lines, says Maus. The CAR T cells controlled or shrank most tumors whether the tumors were intracranial or under the skin. Administered intravenously, the engineered T cells controlled the tumor most effectively when given in combination with temozolomide.
The F-FGln-based PET "reports therapyinduced metabolic changes in these mice long before tumor size changes" on MRI. "This is exactly what glucosebased PET monitors in many other cancers, but has been diffi cult to capture in gliomas," he says.
Additionally,
18
F-FGln-based PET may help separate pseudoprogressiona treatment-related MRI pattern mimicking disease progression-from actual tumor recurrence, "a diffi cult distinction to make in the clinic," Venneti adds.
Testing the agent in patients who had undergone surgery, Venneti and his colleagues saw avid uptake and retention of 18 F-FGln in three patients whose gliomas recurred, but not in three others whose tumors had not. Where 18 F-FDG outlined only part of the tumor in one patient, clearly delineated the same tumor in its entirety-which is important, Venneti notes, because gliomas are highly invasive.
"Hopefully, this agent performs as well outside the brain," says Peter Choyke, MD, director of the NCI's molecular imaging program in Bethesda, MD. "It will be particularly interesting to see whether glutamine uptake in tumors leads to clinical responses for a new generation of drugs targeting glutamine transport and metabolism." ■
Parsing Pancreatic Cancer
In a recently reported study, wholegenome sequencing of 100 pancreatic ductal adenocarcinomas identifi ed four tumor subtypes based on DNA structural variation, distinctions that may help guide treatment choices in the future (Nature 2015;518:495-501).
Current treatments for pancreatic cancer are often toxic and work in only a subset of patients. Matching treatments to patients who might benefi t remains an urgent need, says study co-director Andrew V. Biankin, MD, PhD, of the University of Glasgow in Scotland and the Garvan Institute of Medical Research in Sydney, Australia.
In collaboration with the International Cancer Genome Consortium, the researchers performed deep whole-genome sequencing and copy number-variation analysis on tissue from early-stage tumors. The study extended previous exome sequencing analysis, and found both known and new genes mutated at moderate or high frequency and many genes mutated at low frequency. More importantly, Biankin says, the wholegenome approach revealed structural aberrations that contribute significantly to the overall mutational burden in tumors, including the deletion, amplifi cation, and rearrangement of large pieces of DNA.
Analysis of patterns of structural variation identifi ed four distinct tumor types: stable, locally rearranged, scattered, and unstable. The stable group had the fewest DNA rearrangements, while the locally rearranged and scattered groups showed an intermediate level, clustered on one or two chromosomes or distributed among multiple chromosomes, respectively. The unstable group, accounting for 14% of tumors, showed the most frequent structural changes, with more than 200 per genome. Most of the tumors in this group had mutations in key maintenance and repair enzymes-BRCA1, BRCA2, or PALB2-or displayed a mutational signature of DNA repair defi ciency.
Because DNA repair defi ciency may impart sensitivity to DNA-damaging drugs, the researchers looked at outcomes for patients who had received platinum-based chemotherapy. Of eight patients in the study treated with platinum agents, four of the fi ve with unstable genomes and/or a mutational signature of DNA repair defi ciency responded to treatment. Three patients with other tumor subtypes did not respond.
"These are small numbers, so we have to be cautious, but this is a potential biomarker for us to take forward into clinical trials and start to test whether we can better select patients for specifi c treatment," Biankin says.
That possibility excites Steven D. Leach, MD, of Memorial Sloan Kettering Cancer Center in New York, NY, who was not involved in the work. "For the fi rst time in pancreatic cancer, we see genomic data that may have predictive value in terms of what therapies are likely to work for subsets of patients," he says. ■
NOTED
• Eli Lilly and Company and Beijing, China's Innovent Biologics announced that they will collaborate on the development and potential commercialization of at least three cancer treatments over the next decade. The collaboration will include Lilly's cMet monoclonal antibody (mAb) for possible treatment of nonsmall cell lung cancer and Innovent's mAb targeting CD-20 for possible treatment of hematologic malignancies.
• Apple launched a mobile app to track quality of life of breast cancer survivors. Data will be used to study why some survivors recover faster than others, why symptoms vary, and what can be done to improve problems such as fatigue, mood and cognitive changes, and sleep disturbances. The app is part of Apple's ResearchKit, which is designed to expand participation in research studies.
• At the Endocrine Society's 97th annual meeting in San Diego, CA, researchers presented results of a phase II trial of sunitinib (Sutent; Pfizer) showing that 19 of 24 patients with advanced-stage differentiated thyroid cancer experienced either significant tumor shrinkage or stable disease. The median progressionfree survival was 241 days. Sunitinib is approved for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors.
• Bloomberg Philanthropies and the Bill & Melinda Gates Foundation launched the Anti-Tobacco Trade Litigation Fund to help combat the tobacco industry's use of international trade agreements to threaten countries and prevent them from passing strong tobacco-control laws. The fund, established with $4 million from the organizations, will help low-and middle-income countries draft and defend tobacco-control laws.
• Two out of three people diagnosed with cancer will survive at least 5 years, according to a report published by the Centers for Disease Control and Prevention. The most common cancers continue to be prostate, female breast, lung and bronchus, and colon and rectum, the report noted. 
